Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Receives Consensus Rating of “Buy” from Brokerages

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) has received an average rating of “Buy” from the seven analysts that are presently covering the firm, MarketBeat Ratings reports. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among analysts that have covered the stock in the last year is $48.40.

Several research analysts have commented on the stock. Lucid Cap Mkts raised shares of Ascentage Pharma Group International to a “strong-buy” rating in a report on Monday, December 15th. Truist Financial set a $51.00 price target on Ascentage Pharma Group International in a research note on Monday, November 24th. Oppenheimer assumed coverage on Ascentage Pharma Group International in a report on Thursday, December 4th. They set an “outperform” rating and a $45.00 price target for the company. Piper Sandler began coverage on Ascentage Pharma Group International in a report on Wednesday, November 5th. They set an “overweight” rating and a $48.00 price objective on the stock. Finally, BTIG Research assumed coverage on Ascentage Pharma Group International in a research report on Monday, November 10th. They set a “buy” rating and a $50.00 target price for the company.

Institutional Trading of Ascentage Pharma Group International

Large investors have recently made changes to their positions in the business. Tema Etfs LLC bought a new position in shares of Ascentage Pharma Group International in the 2nd quarter valued at about $610,000. XY Capital Ltd raised its position in Ascentage Pharma Group International by 224.2% during the third quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock valued at $707,000 after purchasing an additional 12,530 shares during the period. UBS Group AG raised its position in Ascentage Pharma Group International by 149.4% during the third quarter. UBS Group AG now owns 18,345 shares of the company’s stock valued at $716,000 after purchasing an additional 10,988 shares during the period. Hsbc Holdings PLC bought a new stake in shares of Ascentage Pharma Group International in the 2nd quarter valued at approximately $391,000. Finally, Citadel Advisors LLC purchased a new position in shares of Ascentage Pharma Group International in the 3rd quarter worth approximately $383,000.

Ascentage Pharma Group International Trading Up 1.4%

Shares of NASDAQ:AAPG opened at $24.52 on Friday. The firm has a fifty day moving average price of $27.52 and a 200 day moving average price of $34.22. Ascentage Pharma Group International has a fifty-two week low of $17.09 and a fifty-two week high of $48.45. The company has a debt-to-equity ratio of 1.31, a quick ratio of 1.53 and a current ratio of 1.54.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.